Assyro AI

FDA Orange Book · active-ingredient family

Atazanavir sulfate; cobicistat

Atazanavir sulfate; cobicistat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:EVOTAZ · NDA 206353

1

Brand (NDA)

0

Generics (ANDA)

2

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
EVOTAZRLDBRISTOLNDA 206353Jan 29, 2015

Listed patents (2)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8148374Sep 03, 2029in 3 yr 3 mo
SubstanceProductU-1279
10039718Oct 06, 2032in 6 yr 5 mo
Product

Atazanavir sulfate; cobicistat — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.